pharma news today glp-1 obesity drugs Weight loss with medicines does not result in a disproportionate GLP-1 agonists and changes in

Because it is not peptide-based, it can survive digestion and be absorbed through the gastrointestinal tract

Additionally, the targeted action of Ipamorelins minimises potential side effects like increased hunger, which can be a challenge with other peptides

472 Elevated extracellular mtDNA in synovial fluid and plasma correlates with autoantibody presence and inflammation, while mtDNA mutations in synovial tissues are associated with increased TNF- and IFN signaling, establishing a self-reinforcing inflammatory cycle

The study appears online in the journal Nature Communications

This exploratory analysis suggests that GLP-1RAs may reduce serum TMAO concentration and thereby the associated higher risk of IHD